These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

607 related articles for article (PubMed ID: 17378928)

  • 21. [Pharyngitis produced by Arcanobacterium haemolyticum].
    Dorobăţ O; Erşcoiu S; Burtea M
    Bacteriol Virusol Parazitol Epidemiol; 1996; 41(3-4):135-40. PubMed ID: 9116401
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Emergence of macrolide resistant Streptococcus pyogenes strains in pediatric patients in France].
    Mariani-Kurkdjian P; Doit C; Deforche D; Brahimi N; Francois M; Van den Abbeele T; Bingen E
    Pathol Biol (Paris); 2004 Oct; 52(8):489-92. PubMed ID: 15465270
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Serotypes and antimicrobial susceptibilities of invasive group A streptococci identified in eastern Black Sea region of Turkey].
    Bayramoğlu G; Topkaya AE; Balıkcı A; Aydın F
    Mikrobiyol Bul; 2011 Jul; 45(3):446-53. PubMed ID: 21935777
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular epidemiology of group A streptococcus causing scarlet fever in northern Taiwan, 2001-2002.
    Chen YY; Huang CT; Yao SM; Chang YC; Shen PW; Chou CY; Li SY
    Diagn Microbiol Infect Dis; 2007 Jul; 58(3):289-95. PubMed ID: 17532590
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular characterization of Group A streptococcal isolates causing scarlet fever and pharyngitis among young children: a retrospective study from a northern Taiwan medical center.
    Wu PC; Lo WT; Chen SJ; Wang CC
    J Microbiol Immunol Infect; 2014 Aug; 47(4):304-10. PubMed ID: 23639381
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [T serotypes distribution and antimicrobial susceptibility of Streptococcus pyogenes in children with pharyngotonsillitis in Asahikawa].
    Sakata H
    Jpn J Antibiot; 2008 Dec; 61(6):359-65. PubMed ID: 19288853
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Occurrence and drug-resistance of beta-hemolytic streptococci].
    Mikołajczyk D; Budzyńska A; Kaczmarek A; Gospodarek E
    Med Dosw Mikrobiol; 2007; 59(4):301-7. PubMed ID: 18416122
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Erythromycin resistance in Streptococcus pyogenes in Italy.
    Bassetti M; Manno G; Collidà A; Ferrando A; Gatti G; Ugolotti E; Cruciani M; Bassetti D
    Emerg Infect Dis; 2000; 6(2):180-3. PubMed ID: 10756153
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Plasmid-Borne erm(T) from invasive, macrolide-resistant Streptococcus pyogenes strains.
    Woodbury RL; Klammer KA; Xiong Y; Bailiff T; Glennen A; Bartkus JM; Lynfield R; Van Beneden C; Beall BW;
    Antimicrob Agents Chemother; 2008 Mar; 52(3):1140-3. PubMed ID: 18180360
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Macrolide and Clindamycin Resistance in Group a Streptococci Isolated From Children With Pharyngitis.
    DeMuri GP; Sterkel AK; Kubica PA; Duster MN; Reed KD; Wald ER
    Pediatr Infect Dis J; 2017 Mar; 36(3):342-344. PubMed ID: 27902646
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Investigation of erythromycin resistance and resistance phenotypes in group A beta hemolytic streptococci].
    Kaya EG; Yücel M; Karakoç AE
    Mikrobiyol Bul; 2006 Jul; 40(3):161-8. PubMed ID: 17001844
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antimicrobial susceptibility survey of Streptococcus pyogenes isolated in Japan from patients with severe invasive group A streptococcal infections.
    Ikebe T; Hirasawa K; Suzuki R; Isobe J; Tanaka D; Katsukawa C; Kawahara R; Tomita M; Ogata K; Endoh M; Okuno R; Watanabe H
    Antimicrob Agents Chemother; 2005 Feb; 49(2):788-90. PubMed ID: 15673769
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Decrease of erythromycin resistance in group A streptococci by change of emm distribution.
    Koh EH; Kim S; Lee NY
    Jpn J Infect Dis; 2008 Jul; 61(4):261-3. PubMed ID: 18653965
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Macrolide prescriptions and erythromycin resistance of Streptococcus pyogenes.
    Gagliotti C; Nobilio L; Milandri M; Moro ML;
    Clin Infect Dis; 2006 Apr; 42(8):1153-6. PubMed ID: 16575736
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Susceptibility of Streptococcus pyogenes to two macrolides in northern Israel.
    Sakran W; Raz R; Chazan B; Koren A; Colodner R
    Int J Antimicrob Agents; 2004 May; 23(5):517-9. PubMed ID: 15120735
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The emergence of erythromycin-resistant Streptococcus pyogenes in Seoul, Korea.
    Cha S; Lee H; Lee K; Hwang K; Bae S; Lee Y
    J Infect Chemother; 2001 Jun; 7(2):81-6. PubMed ID: 11455497
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Streptococcus pyogenes isolated in Portugal: macrolide resistance phenotypes and correlation with T types. Portuguese Surveillance Group for the Study of Respiratory Pathogens.
    Melo-Cristino J; Fernandes ML
    Microb Drug Resist; 1999; 5(3):219-25. PubMed ID: 10566873
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Biotype and antibiotic resistance pattern of group A streptococci.
    Sharma Y; Vishwanath S; Bairy I
    Indian J Pathol Microbiol; 2010; 53(1):187-8. PubMed ID: 20090272
    [No Abstract]   [Full Text] [Related]  

  • 39. Outbreak of scarlet fever associated with emm12 type group A Streptococcus in 2011 in Shanghai, China.
    Chen M; Yao W; Wang X; Li Y; Chen M; Wang G; Zhang X; Pan H; Hu J; Zeng M
    Pediatr Infect Dis J; 2012 Sep; 31(9):e158-62. PubMed ID: 22531238
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Community-based surveillance in the united states of macrolide-resistant pediatric pharyngeal group A streptococci during 3 respiratory disease seasons.
    Tanz RR; Shulman ST; Shortridge VD; Kabat W; Kabat K; Cederlund E; Rippe J; Beyer J; Doktor S; Beall BW;
    Clin Infect Dis; 2004 Dec; 39(12):1794-801. PubMed ID: 15578402
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.